Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Business
Simon Hunt

Weight loss drug Ozempic sales grow nearly 50% in the US, says maker Novo Nordisk

A surge in demand for weight loss drug Ozempic has helped Novo Nordisk post a 25% jump in revenues in the first half of the year, the Danish company said today.

The Bagsværd-based pharma giant said it had seen a 48% rise in sales of its Ozempic treatment in the US, and a near one-third rise in sales worldwide, to hit 56 billion Danish Krone (£6.5 billion).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.